- Conditions
- Staphylococcus Aureus Bacteremia
- Interventions
- Ceftobiprole medocaril, Daptomycin
- Drug
- Lead sponsor
- Basilea Pharmaceutica
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 390 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2022
- U.S. locations
- 5
- States / cities
- Chula Vista, California • West Palm Beach, Florida • Butte, Montana + 2 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–10
of 10
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Staphylococcus Aureus Bacteremia, Staphylococcus Aureus Endocarditis
- Interventions
- Oritavancin Injection
- Drug
- Lead sponsor
- University of Pennsylvania
- Other
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2022
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Infective Endocarditis
- Interventions
- daptomycin, daptomycin and gentamicin
- Drug
- Lead sponsor
- Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2011
- U.S. locations
- 4
- States / cities
- Denver, Colorado • Detroit, Michigan • Philadelphia, Pennsylvania
- Conditions
- Endocarditis, Bacterial, Infective Endocarditis
- Interventions
- daptomycin, vancomycin
- Drug
- Lead sponsor
- Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 38 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2010
- U.S. locations
- 2
- States / cities
- Greenville, North Carolina • Cleveland, Ohio
- Conditions
- Staphylococcus Aureus Bacteremia, Staphylococcus Aureus Endocarditis
- Interventions
- CF-301, Placebo
- Biological · Drug
- Lead sponsor
- ContraFect
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 121 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2019
- U.S. locations
- 31
- States / cities
- Birmingham, Alabama • Sacramento, California • Sylmar, California + 25 more
- Conditions
- MRSA Bloodstream Infection, MRSA Bacteremia, MRSA Right-sided Endocarditis, Covid19
- Interventions
- Exebacase
- Drug
- Lead sponsor
- ContraFect
- Industry
- Eligibility
- 18 Years and older
- U.S. locations
- 2
- States / cities
- Butte, Montana • Toledo, Ohio
- Conditions
- Bacteremia Due to Staphylococcus Aureus, Left Sided Infective Endocarditis (Disorder), Right Sided Infective Endocarditis (Disorder), Endocarditis Infective
- Interventions
- Tonabacase (LSVT-1701)
- Drug
- Lead sponsor
- Lysovant
- Industry
- Eligibility
- 18 Years to 90 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2023
- U.S. locations
- 1
- States / cities
- Butte, Montana
- Conditions
- Staphylococcus Aureus Bacteremia, Staphylococcus Aureus Endocarditis
- Interventions
- Exebacase, Placebo
- Drug
- Lead sponsor
- ContraFect
- Industry
- Eligibility
- 12 Years and older
- Enrollment
- 259 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2022
- U.S. locations
- 55
- States / cities
- Birmingham, Alabama • Orange, California • Sacramento, California + 47 more
- Conditions
- Adenovirus, Anesthesia, Anxiety, Anxiolysis, Autism, Autistic Disorder, Bacterial Meningitis, Bacterial Septicemia, Benzodiazepine, Bipolar Disorder, Bone and Joint Infections, Central Nervous System Infections, Convulsions, Cytomegalovirus Retinitis, Early-onset Schizophrenia Spectrum Disorders, Epilepsy, General Anesthesia, Gynecologic Infections, Herpes Simplex Virus, Infantile Hemangioma, Infection, Inflammation, Inflammatory Conditions, Intra-abdominal Infections, Lower Respiratory Tract Infections, Migraines, Pain, Pneumonia, Schizophrenia, Sedation, Seizures, Skeletal Muscle Spasms, Skin and Skin-structure Infections, Treatment-resistant Schizophrenia, Urinary Tract Infections, Withdrawal, Sepsis, Gram-negative Infection, Bradycardia, Cardiac Arrest, Cardiac Arrhythmia, Staphylococcal Infections, Nosocomial Pneumonia, Neuromuscular Blockade, Methicillin Resistant Staphylococcus Aureus, Endocarditis, Neutropenia, Headache, Fibrinolytic Bleeding, Pulmonary Arterial Hypertension, CMV Retinitis, Hypertension, Chronic Kidney Diseases, Hyperaldosteronism, Hypokalemia, Heart Failure, Hemophilia, Heavy Menstrual Bleeding, Insomnia
- Interventions
- The POPS study is collecting PK data on children prescribed the following drugs of interest per standard of care:
- Drug
- Lead sponsor
- Daniel Benjamin
- Other
- Eligibility
- Up to 21 Years
- Enrollment
- 3,520 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2019
- U.S. locations
- 43
- States / cities
- Anchorage, Alaska • Little Rock, Arkansas • La Jolla, California + 37 more
- Conditions
- Bacteremia
- Interventions
- Telavancin, Vancomycin, Daptomycin, Synthetic penicillin, Cefazolin
- Drug
- Lead sponsor
- Cumberland Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 121 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2018
- U.S. locations
- 1
- States / cities
- Columbus, Ohio